We are live on ! Find out more
KOC

Koss-Olinger Consulting Portfolio holdings

AUM $1.19B
1-Year Est. Return 15.91%
This Fund
S&P 500
This Quarter Est. Return
+5.28%
1 Year Est. Return
+15.91%
3 Year Est. Return
+50.95%
5 Year Est. Return
+57.89%
10 Year Est. Return
AUM
$649M
AUM Growth
+$35M
Cap. Flow
+$5.38M
Cap. Flow %
0.83%
Top 10 Hldgs %
70.02%
Holding
266
New
37
Increased
83
Reduced
80
Closed
51

Sector Composition

Rank Sector Weight
1 Healthcare 2.71%
2 Technology 1.98%
3 Financials 1.45%
4 Consumer Staples 1.43%
5 Communication Services 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LLY icon
101
Eli Lilly
LLY
$1.08T
$524K 0.08%
1,896
-108
-5% -$27.4K
UBER icon
102
Uber
UBER
$145B
$524K 0.08%
12,487
+2,700
+28% +$116K
UNH icon
103
UnitedHealth
UNH
$382B
$522K 0.08%
1,040
-152
-13% -$68.8K
ENIA
104
DELISTED
Enel Amricas S.A. American Depositary Shares (Each representing 50 shares of Common Stock)
ENIA
$522K 0.08%
95,963
+30,139
+46% +$179K
CS
105
DELISTED
Credit Suisse Group
CS
$521K 0.08%
54,000
+15,329
+40% +$153K
JPM icon
106
JPMorgan Chase
JPM
$916B
$517K 0.08%
3,267
+565
+21% +$92.8K
KWEB icon
107
KraneShares CSI China Internet ETF
KWEB
$5.5B
$505K 0.08%
+13,845
New +$637K
MBUU icon
108
Malibu Boats
MBUU
$548M
$498K 0.08%
7,240
+1,870
+35% +$131K
FLRN icon
109
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
$3.07B
$497K 0.08%
16,262
+458
+3% +$14K
DISCK
110
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
$491K 0.08%
21,462
+6,102
+40% +$147K
APH icon
111
Amphenol
APH
$185B
$490K 0.08%
11,200
ABT icon
112
Abbott
ABT
$187B
$474K 0.07%
3,371
+1,030
+44% +$132K
XCEM icon
113
Columbia EM Core ex-China ETF
XCEM
$1.8B
$474K 0.07%
14,941
-148
-1% -$4.76K
BNDX icon
114
Vanguard Total International Bond ETF
BNDX
$82B
$472K 0.07%
8,552
+1,195
+16% +$67.9K
TOTL icon
115
State Street DoubleLine Total Return Tactical ETF
TOTL
$4.1B
$472K 0.07%
9,960
T icon
116
AT&T
T
$164B
$469K 0.07%
25,216
-2,363
-9% -$44.2K
PFE icon
117
Pfizer
PFE
$143B
$465K 0.07%
7,874
-1,911
-20% -$94.7K
TMO icon
118
Thermo Fisher Scientific
TMO
$214B
$463K 0.07%
694
-58
-8% -$36.2K
ATVI
119
DELISTED
Activision Blizzard
ATVI
$461K 0.07%
6,927
-24
-0.3% -$1.64K
DIS icon
120
Walt Disney
DIS
$171B
$450K 0.07%
2,903
-4,917
-63% -$794K
DVA icon
121
DaVita
DVA
$15.5B
$446K 0.07%
3,921
-430
-10% -$46.2K
ZBH icon
122
Zimmer Biomet
ZBH
$18.8B
$443K 0.07%
3,587
+351
+11% +$45.9K
IWM icon
123
iShares Russell 2000 ETF
IWM
$79.1B
$439K 0.07%
1,975
+800
+68% +$181K
AZN icon
124
AstraZeneca
AZN
$269B
$434K 0.07%
3,727
-748
-17% -$88K
LVS icon
125
Las Vegas Sands
LVS
$31.4B
$433K 0.07%
11,492
+2,356
+26% +$90.6K

Similar funds

Koss-Olinger Consulting's Q4 2021 Portfolio in Review

As of Q4 2021, Koss-Olinger Consulting held 266 positions worth $649M, up 5.7% from $614M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Koss-Olinger Consulting's Q4 2021 filing shows 37 new, 83 increased, 80 reduced and 51 closed positions. Its largest new stake was Vanguard FTSE Emerging Markets ETF: 40,760 shares worth $2.02M. The largest sale was VanEck Emerging Markets High Yield Bond ETF, an estimated $34.6M.

By sector, the portfolio is most concentrated in Healthcare at 2.7% of assets, down from 3.2% a quarter earlier, followed by Technology and Financials.

  • Koss-Olinger Consulting's largest Q4 2021 buy was Vanguard FTSE Emerging Markets ETF: 40,760 shares worth $2.02M.
  • Koss-Olinger Consulting added most to Vanguard Total Bond Market in Q4 2021, an estimated $36.2M increase.
  • Koss-Olinger Consulting's biggest Q4 2021 reduction was VanEck Emerging Markets High Yield Bond ETF, cutting an estimated $34.6M.
  • Koss-Olinger Consulting fully exited Arcturus Therapeutics in Q4 2021, selling an estimated $2.09M.
  • Koss-Olinger Consulting's ten largest holdings make up 70% of its $649M portfolio in Q4 2021.
  • Koss-Olinger Consulting opened 37 new positions and closed 51 in Q4 2021.
  • Koss-Olinger Consulting's portfolio value rose 5.7% quarter-over-quarter to $649M.

Based on Koss-Olinger Consulting's 13F filing for Q4 2021, filed 7 Feb 2022.